Overview

In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 5 sites of the four oral ACTS artemether-lumefantrine (AL), Amodiaquine-Artesunate (AQ-AS), Dihydroartemisinin-Piperaquine (DHP) and Pironaridine-Artesunate for the treatment of uncomplicated malaria in children aged<5 years.

Phase:

Phase 4

Details

Lead Sponsor:

Centro de Investigacao em Saude de Manhica

Collaborator:

United States Agency for International Development (USAID)

Treatments:

Artemether, Lumefantrine Drug Combination